Lymphocytes are the central mediators of cellular and humoral immunity, but they depend on dendritic and other reticuloendothelial cells during development and for the generation of acquired immunity. Lymphocyte function and interactions with dendritic cells are regulated through cell-surface molecules that mediate intercellular communication, generate transmembrane signals, and direct lymphocyte development and localization within tissues. Aberrant lymphocyte and dendritic cell functions contribute to immunodeficiencies, autoimmune conditions, age-related defects in immunity, and malignancies.
The aim of these studies is to examine the function of CD83, a cell-surface receptor that we first identified as a member of the immunoglobulin superfamily predominantly expressed by dendritic cells in humans. Based on the remarkable phenotype of CD83-deficient (CD83-/-) mice that we have generated, CD83 functions as an essential receptor for T lymphocyte selection and/or lineage commitment. Thus, CD83 engagement uniquely represents a new regulatory step for CD4+ T cell development in the thymus, but is likely to have additional functions in the immune system. We propose that CD83 expressed by mouse dendritic and thymic epithelial cells binds extracellular ligand(s), which inform developing and mature lymphocytes of their extracellular microenvironment in vivo. These signals may regulate lymphocyte activation and survival in the periphery and thereby regulate cellular and humoral immune responses.
Three specific aims are designed to test this hypothesis and to further our knowledge of how CD83 regulates normal lymphocyte development and function.
Specific aim 1 will determine how CD83 regulates thymocyte development in vivo and in vitro.
Specific aim 2 will determine whether and how CD83 regulates peripheral lymphocyte survival.
In specific aim 3, we will determine whether CD83 binding to extracellular ligand(s) regulates lymphocyte development and function in vivo by identifying and characterizing CD83 ligands expressed by mouse thymocytes. Since CD83 expression provides an important regulatory checkpoint for helper T cell development, understanding its function may provide mechanisms for modulating humoral immunity and for the treatment of immunodeficiency, autoimmunity and malignancies

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA098492-02
Application #
6951080
Study Section
Immunobiology Study Section (IMB)
Program Officer
Mccarthy, Susan A
Project Start
2004-09-20
Project End
2008-06-30
Budget Start
2005-09-01
Budget End
2006-06-30
Support Year
2
Fiscal Year
2005
Total Cost
$284,130
Indirect Cost
Name
Duke University
Department
Neurosciences
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Matsushita, Takashi; Yanaba, Koichi; Bouaziz, Jean-David et al. (2008) Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 118:3420-30
Prazma, Charlene M; Tedder, Thomas F (2008) Dendritic cell CD83: a therapeutic target or innocent bystander? Immunol Lett 115:1-8
Yanaba, Koichi; Bouaziz, Jean-David; Haas, Karen M et al. (2008) A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28:639-50
Kuwano, Yoshihiro; Prazma, Charlene M; Yazawa, Norihito et al. (2007) CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells. Int Immunol 19:977-92
Prazma, Charlene M; Yazawa, Norihito; Fujimoto, Yoko et al. (2007) CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo. J Immunol 179:4550-62
Venturi, Guglielmo M; Conway, Rochelle M; Steeber, Douglas A et al. (2007) CD25+CD4+ regulatory T cell migration requires L-selectin expression: L-selectin transcriptional regulation balances constitutive receptor turnover. J Immunol 178:291-300